Effect of ranitidine bismuth citrate on postprandial plasma gastrin and pepsinogens.
Ranitidine bismuth citrate was compared with an equipotent dose of ranitidine, to determine whether the former, by an anti-Helicobacter pylori activity, would counteract the rise of gastrin resulting from ranitidine's gastric acid antisecretory activity. Twenty four men with duodenal ulcers were studied before and on the 8th day of dosing with either ranitidine bismuth citrate 800 mg twice daily or ranitidine 300 mg twice daily (double blind, randomised, parallel groups). Fasting and postprandial plasma gastrin and plasma pepsinogen I and II concentrations were measured, and a 13C-urea breath test was performed before and on the 8th day of dosing. The 13C-urea breath tests were positive in 21 patients before dosing and remained positive in nine of nine of the ranitidine dosed patients, whereas only two of 12 patients treated with ranitidine bismuth citrate remained positive. The expected rise in meal stimulated plasma gastrin with ranitidine was seen in the 12 patients who received ranitidine but, despite suppression of H pylori urease activity in 10 of 12 patients taking ranitidine bismuth citrate, there was no attenuation of the meal stimulated gastrin rise. There was no significant difference in the mean derived (4 hour) plasma pepsinogen I and II concentrations after dosing with ranitidine or ranitidine bismuth citrate.
Fraser
A G
AG
University Department of Medicine, Royal Free Hospital School of Medicine, London.
Lam
W M
WM
Luk
Y W
YW
Sercombe
J
J
Sawyerr
A M
AM
Hudson
M
M
Samloff
I M
IM
Pounder
R E
RE
D000328:Adult; D000368:Aged; D001729:Bismuth / Q000627:therapeutic use*; D001944:Breath Tests; D002951:Citrates / Q000627:therapeutic use*; D004381:Duodenal Ulcer / Q000097:blood / Q000188:drug therapy; D005502:Food; D005755:Gastrins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use; D010435:Pepsinogens / Q000097:blood*; D011899:Ranitidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
D002951:Citrates; D005755:Gastrins; D009942:Organometallic Compounds; D010435:Pepsinogens; C073340:ranitidine bismuth citrate; D011899:Ranitidine; C002791:bismuth tripotassium dicitrate; D001729:Bismuth